J M Wolff

Summary

Country: Germany

Publications

  1. doi request reprint [GnRH antagonists--a new therapy option for advanced prostate cancer]
    J M Wolff
    Urologische Klinik am St Cornelius Hospital, Allgemeines Krankenhaus, Viersen GmbH, Heesstrasse 10, Viersen
    Aktuelle Urol 40:159-63. 2009
  2. doi request reprint Drivers for change in the management of prostate cancer - guidelines and new treatment techniques
    J M Wolff
    Department of Urology, Viersen General Hospital, Viersen, Germany
    BJU Int 109:33-41. 2012
  3. doi request reprint [Intermittent androgen deprivation in advanced prostate cancer: a review]
    J M Wolff
    Urologische Klinik, AKH Viersen, Viersen
    Aktuelle Urol 43:115-20. 2012
  4. ncbi request reprint Intermittent androgen ablation as a treatment for prostate cancer
    J M Wolff
    Department of Urology, University of Rostock, Germany
    Front Radiat Ther Oncol 36:66-71. 2002

Detail Information

Publications4

  1. doi request reprint [GnRH antagonists--a new therapy option for advanced prostate cancer]
    J M Wolff
    Urologische Klinik am St Cornelius Hospital, Allgemeines Krankenhaus, Viersen GmbH, Heesstrasse 10, Viersen
    Aktuelle Urol 40:159-63. 2009
    ..In contrast, gonadotrophin releasing hormone (GnRH) antagonists do not induce a testosterone surge and the level of testosterone decreases as rapidly as that known from a surgical castration...
  2. doi request reprint Drivers for change in the management of prostate cancer - guidelines and new treatment techniques
    J M Wolff
    Department of Urology, Viersen General Hospital, Viersen, Germany
    BJU Int 109:33-41. 2012
    ..Novel techniques such as proton beam or carbon ion radiotherapy, which may offer improved and more localized dose distribution with reduced damage to normal tissue, are also examined...
  3. doi request reprint [Intermittent androgen deprivation in advanced prostate cancer: a review]
    J M Wolff
    Urologische Klinik, AKH Viersen, Viersen
    Aktuelle Urol 43:115-20. 2012
    ..Although data about quality of life and overall survival are still limited, results seem to be comparable. In order to decide which patient groups are most likely to benefit from IAB, final phase III results need to be available...
  4. ncbi request reprint Intermittent androgen ablation as a treatment for prostate cancer
    J M Wolff
    Department of Urology, University of Rostock, Germany
    Front Radiat Ther Oncol 36:66-71. 2002